WALTHAM,
Mass., Sept. 6, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a commercial stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that on September 1, 2024 the Company granted an
inducement award to purchase up to 60,000 shares of common stock to
one new employee under the Company's 2023 Inducement Plan. The
stock options will vest over four years, with 25% of the underlying
shares vesting on the one-year anniversary of the vesting
commencement date and 1/48th of the underlying shares vesting
monthly thereafter over 36 months, subject to the employee's
continued service relationship with Syndax through the applicable
vesting dates.
About Syndax
Syndax Pharmaceuticals is a commercial stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include revumenib, a highly
selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), a
monoclonal antibody that blocks the colony stimulating factor 1
(CSF-1) receptor. Syndax is working to unlock the full potential of
its pipeline and is conducting several clinical trials across the
continuum of treatment for both revumenib and Niktimvo. For more
information, please visit www.syndax.com/ or follow the Company on
X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
View original
content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302240820.html
SOURCE Syndax Pharmaceuticals, Inc.
